US · guidance
CMS Pub. 100-03, ch. 1, § 110.15
Ultrafiltration, Hemoperfusion and Hemofiltration
CIM 35-38
A. Ultrafiltration
This is a process for removing excess fluid from the blood through the dialysis membrane by means of
pressure. It is not a substitute for dialysis. Ultrafiltration is utilized in cases where excess fluid cannot be
removed easily during the regular course of hemodialysis. When it is performed, it is commonly done
during the first hour or two of each hemodialysis on patients who, e.g., have refractory edema.
Ultrafiltration is a covered procedure under the Medicare program (effective for services performed on and
after September 1, 1979)
Predialysis Ultrafiltration
While this procedure requires additional staff care, the facility dialysis rate is intended to cover the full range
of complicated and uncomplicated nonacute dialysis treatments. Therefore, no additional facility charge is
recognized for predialysis ultrafiltration. The physician’s role in ultrafiltration varies with the stability of
the patient’s condition. In unstable patients, the physician may need to be present at the initiation of
dialysis, and available either in-house or in close proximity to monitor the patient carefully. In patients who
are relatively stable, but who seem to accumulate excessive weight gain, the procedure requires only a
modest increase in physician involvement over routine outpatient hemodialysis.
Occasionally, medical complications may occur which require that ultrafiltration be performed separate
from the dialysis treatment, and in these cases an additional charge can be recognized. However, the claim
must be documented as to why the ultrafiltration could not have been performed at the same time as the
dialysis.
B. Hemoperfusion
This is a process which removes substances from the blood using a charcoal or resin artificial kidney. When
used in the treatment of life threatening drug overdose, hemoperfusion is a covered service for patients with
or without renal failure. Hemoperfusion generally requires a physician to be present to initiate treatment and
to be present in the hospital or an adjacent medical office during the entire procedure, as changes may be
sudden. Special staff training and equipment are required.
Develop charges for hemoperfusion in the same manner as for any new or unusual service. One or two
treatments are usually all that is necessary to remove the toxic compound; document additional treatments.
Hemoperfusion may be performed concurrently with dialysis, and in those cases payment for the
hemoperfusion reflects only the additional care rendered over and above the care given with dialysis.
The effects of using hemoperfusion to improve the results of chronic hemodialysis are not known.
Therefore, hemoperfusion is not a covered service when used to improve the results of hemodialysis. In
addition, it has not been demonstrated that the use of hemoperfusion in conjunction with deferoxamine
(DFO), in treating symptomatic patients with iron overload, is efficacious. There is also a paucity of data
regarding its efficacy in treating asymptomatic patients with iron overload. Therefore, hemoperfusion used
in conjunction with DFO in treating patients with iron overload is not a covered service; i.e., it is not
considered reasonable and necessary within the meaning of §1862(a)(1) of the Act.
However, the use of hemoperfusion in conjunction with DFO for the treatment of patients with aluminum
toxicity has been demonstrated to be clinically efficacious and is therefore regarded as a covered service.
C. Hemofiltration
This is a process which removes fluid, electrolytes and other low molecular weight toxic substances from
the blood by filtration through hollow artificial membranes and may be routinely performed in 3 weekly
sessions. Hemofiltration (which is also known as diafiltration) is a covered procedure under Medicare and is
a safe and effective technique for the treatment of ESRD patients and an alternative to peritoneal dialysis
and hemodialysis. In contrast to both hemodialysis and peritoneal dialysis treatments which eliminate
dissolved substances via diffusion across semipermeable membranes, hemofiltration mimics the filtration
process of the normal kidney. The technique requires an arteriovenous access. Hemofiltration may be
performed either in facility or at home.
The procedure is most advantageous when applied to high-risk unstable patients, such as older patients with
cardiovascular diseases or diabetes, because there are fewer side effects such as hypotension, hypertension
or volume overload.
History
(Rev. 1, 10-03-03)
Provenance
- Source
- cms.gov
- Retrieved
- 2026-08-25
- Edition
- iom-2026-08-25
- Content hash
f682282e5e1f973ba8b6152e58116ab54bd3b3d0cdf6efce971b28774a3c18c8
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.